Recent Updates
Recently added Catalysts
ABBV

AbbVie Inc. Key Product Revenues Quarterly Trend Analysis (Unaudited, in millions) 1Q19 2Q19 3Q19 4Q19 FY19 1Q20 U.S. Int'l. Total U.S. Int'l. Total U.S. Int'l. Total U.S. Int'l. Total U.S. Int'l. Total U.S. Int'l. Total

Wednesday, July 29, 2020 1 min read
Key Takeaway: Key Product Revenues Quarterly Trend Analysis (Unaudited, in millions) a Reflects profit sharing for Imbruvica international revenues. * Represents product(s) acquired as part of the Allergan acquisition. Key Product Revenues Quarterly Comparable Historical Trend Analysis a

Full Press Release Details

Key Product Revenues
Quarterly Trend Analysis
(Unaudited, in millions)
1Q19 2Q19 3Q19 4Q19 FY19 1Q20
U.S. Int'l. Total U.S. Int'l. Total U.S. Int'l. Total U.S. Int'l. Total U.S. Int'l. Total U.S. Int'l. Total
NET REVENUES $ 5,270 $ 2,558 $ 7,828 $ 5,964 $ 2,291 $ 8,255 $ 6,244 $ 2,235 $ 8,479 $ 6,429 $ 2,275 $ 8,704 $ 23,907 $ 9,359 $ 33,266 $ 6,158 $ 2,461 $ 8,619
Immunology 3,215 1,231 4,446 3,835 1,083 4,918 3,977 1,064 5,041 4,195 971 5,166 15,222 4,349 19,571 4,004 1,085 5,089
Humira 3,215 1,231 4,446 3,793 1,077 4,870 3,887 1,049 4,936 3,969 948 4,917 14,864 4,305 19,169 3,656 1,047 4,703
Skyrizi - - - 42 6 48 76 15 91 193 23 216 311 44 355 266 34 300
Rinvoq - - - - - - 14 - 14 33 - 33 47 - 47 82 4 86
Hematologic Oncology 934 239 1,173 1,003 265 1,268 1,184 294 1,478 1,230 317 1,547 4,351 1,115 5,466 1,167 382 1,549
Imbruvica a 829 193 1,022 886 213 1,099 1,042 215 1,257 1,073 223 1,296 3,830 844 4,674 966 266 1,232
Venclexta 105 46 151 117 52 169 142 79 221 157 94 251 521 271 792 201 116 317
Aesthetics - - - - - - - - - - - - - - - - - -
Botox Cosmetic* - - - - - - - - - - - - - - - - - -
Juvederm Collection* - - - - - - - - - - - - - - - - - -
Other Aesthetics* - - - - - - - - - - - - - - - - - -
Neuroscience 22 89 111 24 91 115 26 91 117 25 93 118 97 364 461 25 99 124
Botox Therapeutic* - - - - - - - - - - - - - - - - - -
Vraylar* - - - - - - - - - - - - - - - - - -
Duodopa 22 89 111 24 91 115 26 91 117 25 93 118 97 364 461 25 99 124
Ubrelvy* - - - - - - - - - - - - - - - - - -
Other Neuroscience* - - - - - - - - - - - - - - - - - -
Eye Care - - - - - - - - - - - - - - - - - -
Lumigan/Ganfort* - - - - - - - - - - - - - - - - - -
Alphagan/Combigan* - - - - - - - - - - - - - - - - - -
Restasis* - - - - - - - - - - - - - - - - - -
Other Eye Care* - - - - - - - - - - - - - - - - - -
Women's Health 13 - 13 18 1 19 27 - 27 33 1 34 91 2 93 30 1 31
Lo Loestrin* - - - - - - - - - - - - - - - - - -
Orilissa 13 - 13 18 1 19 27 - 27 33 1 34 91 2 93 30 1 31
Other Women's Health* - - - - - - - - - - - - - - - - - -
Other Key Products 1,003 425 1,428 1,024 425 1,449 1,017 370 1,387 976 367 1,343 4,020 1,587 5,607 910 363 1,273
Mavyret 403 387 790 396 384 780 368 327 695 306 322 628 1,473 1,420 2,893 234 325 559
Creon 227 - 227 257 - 257 265 - 265 292 - 292 1,041 - 1,041 276 - 276
Lupron 191 38 229 168 41 209 187 43 230 174 45 219 720 167 887 195 38 233
Linzess/Constella* - - - - - - - - - - - - - - - - - -
Synthroid 182 - 182 203 - 203 197 - 197 204 - 204 786 - 786 205 - 205
a Reflects profit sharing for Imbruvica international revenues.
* Represents product(s) acquired as part of the Allergan acquisition.
Key Product Revenues
Quarterly Comparable Historical Trend Analysis a, b
(Unaudited, in millions)
1Q19 2Q19 3Q19 4Q19 FY19 1Q20
U.S. Int'l. Total U.S. Int'l. Total U.S. Int'l. Total U.S. Int'l. Total U.S. Int'l. Total U.S. Int'l. Total
NET REVENUES $ 8,031 $ 3,359 $ 11,390 $ 9,130 $ 3,137 $ 12,267 $ 9,334 $ 3,069 $ 12,403 $ 9,751 $ 3,192 $ 12,943 $ 36,246 $ 12,757 $ 49,003 $ 9,018 $ 3,151 $ 12,169
Immunology 3,215 1,231 4,446 3,835 1,083 4,918 3,977 1,064 5,041 4,195 971 5,166 15,222 4,349 19,571 4,004 1,085 5,089
Humira 3,215 1,231 4,446 3,793 1,077 4,870 3,887 1,049 4,936 3,969 948 4,917 14,864 4,305 19,169 3,656 1,047 4,703
Skyrizi - - - 42 6 48 76 15 91 193 23 216 311 44 355 266 34 300
Rinvoq - - - - - - 14 - 14 33 - 33 47 - 47 82 4 86
Hematologic Oncology 934 239 1,173 1,003 265 1,268 1,184 294 1,478 1,230 317 1,547 4,351 1,115 5,466 1,167 382 1,549
Imbruvica c 829 193 1,022 886 213 1,099 1,042 215 1,257 1,073 223 1,296 3,830 844 4,674 966 266 1,232
Venclexta 105 46 151 117 52 169 142 79 221 157 94 251 521 271 792 201 116 317
Aesthetics 648 353 1,001 737 357 1,094 646 358 1,004 742 413 1,155 2,773 1,481 4,254 587 250 837
Botox Cosmetic* 230 147 377 252 176 428 238 166 404 272 183 455 992 672 1,664 213 114 327
Juvederm Collection* 129 158 287 157 173 330 135 144 279 167 181 348 588 656 1,244 108 113 221
Other Aesthetics* 289 48 337 328 8 336 273 48 321 303 49 352 1,193 153 1,346 266 23 289
Neuroscience 780 185 965 903 192 1,095 923 189 1,112 1,005 198 1,203 3,611 764 4,375 919 192 1,111
Botox Therapeutic* 403 94 497 454 99 553 439 93 532 469 103 572 1,765 389 2,154 402 89 491
Vraylar* 148 - 148 201 - 201 241 - 241 291 - 291 881 - 881 285 - 285
Duodopa 22 89 111 24 91 115 26 91 117 25 93 118 97 364 461 25 99 124
Ubrelvy* - - - - - - - - - - - - - - - 13 - 13
Other Neuroscience* 207 2 209 224 2 226 217 5 222 220 2 222 868 11 879 194 4 198
Eye Care 505 292 797 594 327 921 577 313 890 610 319 929 2,286 1,251 3,537 607 283 890
Lumigan/Ganfort* 70 85 155 69 91 160 69 89 158 79 96 175 287 361 648 81 81 162
Alphagan/Combigan* 91 38 129 98 41 139 94 40 134 95 43 138 378 162 540 92 37 129
Restasis* 248 10 258 315 12 327 300 10 310 331 18 349 1,194 50 1,244 314 11 325
Other Eye Care* 96 159 255 112 183 295 114 174 288 105 162 267 427 678 1,105 120 154 274
Women's Health 230 8 238 262 10 272 280 11 291 285 13 298 1,057 42 1,099 219 9 228
Lo Loestrin* 129 3 132 150 3 153 167 3 170 161 5 166 607 14 621 114 3 117
Orilissa 13 - 13 18 1 19 27 - 27 33 1 34 91 2 93 30 1 31
Other Women's Health* 88 5 93 94 6 100 86 8 94 91 7 98 359 26 385 75 5 80
Other Key Products 1,181 430 1,611 1,231 430 1,661 1,237 377 1,614 1,216 374 1,590 4,865 1,611 6,476 1,103 370 1,473
Mavyret 403 387 790 396 384 780 368 327 695 306 322 628 1,473 1,420 2,893 234 325 559
Creon 227 - 227 257 - 257 265 - 265 292 - 292 1,041 - 1,041 276 - 276
Lupron 191 38 229 168 41 209 187 43 230 174 45 219 720 167 887 195 38 233
Linzess/Constella* 178 5 183 207 5 212 220 7 227 240 7 247 845 24 869 193 7 200
Synthroid 182 - 182 203 - 203 197 - 197 204 - 204 786 - 786 205 - 205
a Comparable historical net revenues include total revenues for all reported periods for both AbbVie and Allergan products as if the acquisition had closed on January 1, 2019.
b All historically reported Allergan revenues have been recast to conform to AbbVie's revenue recognition accounting policies and reporting conventions for certain rebates and discounts. Historically reported Allergan revenues also exclude Zenpep and Viokace product revenues, which were both divested as part of the acquisition, as well as specified items.
c Reflects profit sharing for Imbruvica international revenues.
* Represents product(s) acquired as part of the Allergan acquisition.
Tags: ABBV Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jul 29, 2020